Details of Disease

General Information of Disease (ID: DISFSUKQ)

• Disease Name: Membranous glomerulonephritis
• Synonyms: membranous nephropathy; membranous Glomerulonephropathy
• Definition: A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.
• Disease Hierarchy:
  DISPZIQ3: Glomerulonephritis
  DISFSUKQ: Membranous glomerulonephritis
• Disease Identifiers:
  MONDO ID: MONDO_0005376
  MESH ID: D015433
  UMLS CUI: C0017665
  MedGen ID: 42231
  HPO ID: HP:0012578
  SNOMED CT ID: 77182004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Belimumab	DM3OBQF	Approved	Antibody	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 31 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
APOH	TT2OUI9	Limited	Biomarker	[2]
APOL1	TTDB8PW	Limited	Genetic Variation	[3]
BRSK1	TTV6WMQ	Limited	Biomarker	[4]
CNTN1	TTPR8FK	Limited	Biomarker	[5]
CTH	TTLQUZS	Limited	Genetic Variation	[6]
HLA-DQA1	TTU2I3J	Limited	Genetic Variation	[7]
MLYCD	TT9Z4YD	Limited	Genetic Variation	[8]
MTNR1A	TT0WAIE	Limited	Altered Expression	[9]
PDGFC	TTOABM9	Limited	Biomarker	[10]
USP2	TTUEQ1W	moderate	Biomarker	[11]
ABCA1	TTJW1GN	Strong	Biomarker	[12]
ALB	TTFNGC9	Strong	Biomarker	[13]
APOA1	TT5S8DR	Strong	Biomarker	[14]
APOE	TTKS9CB	Strong	Biomarker	[15]
C3	TTJGY7A	Strong	Biomarker	[16]
CD40	TT1ERKL	Strong	Therapeutic	[17]
CDKN1B	TTLGFVW	Strong	Biomarker	[18]
CFH	TTUW6OP	Strong	Biomarker	[19]
CYP21A2	TTP4GLG	Strong	Genetic Variation	[20]
EHMT2	TTS6RZT	Strong	Genetic Variation	[20]
GAA	TTLPC70	Strong	Biomarker	[21]
HLA-DRB1	TTUXSTW	Strong	Genetic Variation	[22]
MAP3K5	TTOQCD8	Strong	Biomarker	[23]
MS4A1	TTUE541	Strong	Biomarker	[24]
NQO1	TT8XK6L	Strong	Altered Expression	[25]
PLG	TTP86E2	Strong	Biomarker	[26]
PTGER3	TTPNGDE	Strong	Biomarker	[27]
RHOA	TTP2U16	Strong	Biomarker	[28]
SPARC	TTBQFM7	Strong	Biomarker	[29]
TBXAS1	TTKNWZ4	Strong	Biomarker	[30]
TNFRSF12A	TTKPS7V	Strong	Altered Expression	[31]

This Disease Is Related to 42 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CD5L	OTPY4WQR	Limited	Biomarker	[32]
CDC42BPG	OTY8RFVW	Limited	Biomarker	[33]
CHRDL1	OTGMWVVA	Limited	Biomarker	[34]
CLCN5	OT9YXZSO	Limited	Biomarker	[35]
EIF4A2	OT08H03R	Limited	Biomarker	[36]
FIS1	OT2HL10J	Limited	Biomarker	[37]
HELT	OTI77HDK	Limited	Genetic Variation	[10]
HLA-DQA2	OT1DH0N9	Limited	Genetic Variation	[38]
HLA-DRB3	OT5PM9N7	Limited	Biomarker	[39]
KLHDC8B	OTKP6LCR	Limited	Biomarker	[34]
NEFH	OTMSCW5I	Limited	Altered Expression	[40]
NPNT	OTFZAO1G	Limited	Altered Expression	[41]
P3H4	OTZPXYSH	Limited	Biomarker	[42]
PDLIM2	OTEURRPD	Limited	Altered Expression	[43]
PTER	OTBYJHDG	Limited	Biomarker	[44]
RABEP2	OTO61X27	Limited	Biomarker	[45]
EXT1	OTRPALJK	moderate	Biomarker	[46]
EXT2	OT8IR5QN	moderate	Biomarker	[46]
A2M	OTFTX90K	Strong	Biomarker	[47]
ACTN4	OTCNZAJ5	Strong	Biomarker	[48]
BTNL2	OTTTEMZA	Strong	Genetic Variation	[20]
C7	OTZ27VJN	Strong	Biomarker	[49]
EGFL8	OTECTJ7K	Strong	Genetic Variation	[20]
GPANK1	OT1TN2KT	Strong	Genetic Variation	[20]
HLA-DMB	OT17HGXJ	Strong	Genetic Variation	[20]
KRT20	OT4RB40L	Strong	Biomarker	[24]
LRPAP1	OT6DVD2Q	Strong	Biomarker	[50]
MUCL3	OTGAD3I0	Strong	Genetic Variation	[20]
NPHS1	OT21JD3P	Strong	Altered Expression	[51]
NPHS2	OTLCNUII	Strong	Biomarker	[52]
PLA2G6	OT5FL0WU	Strong	Biomarker	[53]
POU5F1	OTDHHN7O	Strong	Genetic Variation	[20]
PPT2	OTD5VJ9A	Strong	Genetic Variation	[20]
PRRC2A	OTBX6FM5	Strong	Genetic Variation	[20]
PSORS1C1	OT9HK436	Strong	Genetic Variation	[20]
PTPRU	OTHDO0QG	Strong	Biomarker	[54]
RNF5	OTDQGI37	Strong	Genetic Variation	[20]
SFTA2	OTVRIUIV	Strong	Genetic Variation	[20]
STK19	OTYM6437	Strong	Genetic Variation	[20]
SYNPO	OTICDJAB	Strong	Altered Expression	[55]
TCF19	OT7NKLF9	Strong	Genetic Variation	[20]
TSBP1	OT5GE8IO	Strong	Genetic Variation	[20]

References

• [1] [Membranous glomerulonephritis (MGN), ongoing studies]. G Ital Nefrol. 2017 Sep 28;34(5):113-118.
• [2] Antiphospholipid Antibodies in Patients with Membranous Nephropathy.Nephron. 2019;143(4):228-233. doi: 10.1159/000501857. Epub 2019 Aug 27.
• [3] One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants.Adv Anat Pathol. 2019 May;26(3):215-219. doi: 10.1097/PAP.0000000000000221.
• [4] Both Peripheral Blood and Urinary miR-195-5p, miR-192-3p, miR-328-5p and Their Target Genes PPM1A, RAB1A and BRSK1 May Be Potential Biomarkers for Membranous Nephropathy.Med Sci Monit. 2019 Mar 13;25:1903-1916. doi: 10.12659/MSM.913057.
• [5] Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy: An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey.Front Neurol. 2018 Nov 27;9:997. doi: 10.3389/fneur.2018.00997. eCollection 2018.
• [6] Network analysis of membranous glomerulonephritis based on metabolomics data.Mol Med Rep. 2018 Nov;18(5):4197-4212. doi: 10.3892/mmr.2018.9477. Epub 2018 Sep 12.
• [7] Interaction between PLA2R1 and HLA-DQA1 variants contributes to the increased genetic susceptibility to membranous nephropathy in Western China.Nephrology (Carlton). 2019 Sep;24(9):919-925. doi: 10.1111/nep.13536. Epub 2019 Apr 29.
• [8] CD20-positive infiltrates in human membranous glomerulonephritis.J Nephrol. 2005 May-Jun;18(3):328-33.
• [9] Role of melatonin receptor 1A and pituitary homeobox-1 coexpression in protecting tubular epithelial cells in membranous nephropathy.J Pineal Res. 2018 Aug;65(1):e12482. doi: 10.1111/jpi.12482. Epub 2018 Mar 25.
• [10] PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases.J Am Soc Nephrol. 2003 May;14(5):1145-53. doi: 10.1097/01.asn.0000062964.75006.a8.
• [11] Expression of USP2-69 in mesangial cells in vivo and in vitro.Pathol Int. 2010 Mar;60(3):184-92. doi: 10.1111/j.1440-1827.2010.02496.x.
• [12] Experimental glomerulopathy alters renal cortical cholesterol, SR-B1, ABCA1, and HMG CoA reductase expression.Am J Pathol. 2003 Jan;162(1):283-91. doi: 10.1016/S0002-9440(10)63819-9.
• [13] Therapeutic Effect of a Novel Nano-Drug Delivery System on Membranous Glomerulonephritis Rat Model Induced by Cationic Bovine Serum.AAPS PharmSciTech. 2018 Jul;19(5):2195-2202. doi: 10.1208/s12249-018-1034-z. Epub 2018 May 3.
• [14] Apolipoprotein AI levels are increased in part as a consequence of reduced catabolism in nephrotic rats.Am J Physiol. 1995 Mar;268(3 Pt 2):F532-40. doi: 10.1152/ajprenal.1995.268.3.F532.
• [15] Proteinuria decreases tissue lipoprotein receptor levels resulting in altered lipoprotein structure and increasing lipid levels.Kidney Int. 2012 Nov;82(9):990-9. doi: 10.1038/ki.2012.244. Epub 2012 Jul 11.
• [16] Resveratrol ameliorates renal damage, increases expression of heme oxygenase-1, and has anti-complement, anti-oxidative, and anti-apoptotic effects in a murine model of membranous nephropathy.PLoS One. 2015 May 8;10(5):e0125726. doi: 10.1371/journal.pone.0125726. eCollection 2015.
• [17] DNA vaccine encoding CD40 targeted to dendritic cells in situ prevents the development of Heymann nephritis in rats.Kidney Int. 2013 Feb;83(2):223-32. doi: 10.1038/ki.2012.374. Epub 2012 Dec 5.
• [18] UCH-L1 induces podocyte hypertrophy in membranous nephropathy by protein accumulation.Biochim Biophys Acta. 2014 Jul;1842(7):945-58. doi: 10.1016/j.bbadis.2014.02.011. Epub 2014 Feb 28.
• [19] Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy.Nephron Clin Pract. 2004;97(4):c147-53. doi: 10.1159/000079174.
• [20] Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.N Engl J Med. 2011 Feb 17;364(7):616-26. doi: 10.1056/NEJMoa1009742.
• [21] Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.Pediatrics. 2004 Oct;114(4):e532-5. doi: 10.1542/peds.2003-0988-L.
• [22] HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy.Kidney Int. 2018 Nov;94(5):974-982. doi: 10.1016/j.kint.2018.06.005. Epub 2018 Aug 30.
• [23] Role of apoptosis signal-regulating kinase 1 in complement-mediated glomerular epithelial cell injury.Mol Immunol. 2008 Apr;45(8):2236-46. doi: 10.1016/j.molimm.2007.11.013. Epub 2008 Feb 21.
• [24] Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab.Nephron. 2020;144(1):30-35. doi: 10.1159/000501858. Epub 2019 Jul 23.
• [25] Renoprotective Effects Of Isoliquiritin Against Cationic Bovine Serum Albumin-Induced Membranous Glomerulonephritis In Experimental Rat Model Through Its Anti-Oxidative And Anti-Inflammatory Properties.Drug Des Devel Ther. 2019 Oct 30;13:3735-3751. doi: 10.2147/DDDT.S213088. eCollection 2019.
• [26] Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen.J Biol Chem. 1991 Jun 15;266(17):10825-9.
• [27] COX-2 inhibition and prostaglandin receptors in experimental nephritis.Eur J Clin Invest. 2003 Nov;33(11):969-75. doi: 10.1046/j.1365-2362.2003.01256.x.
• [28] Role of Rho-GTPases in complement-mediated glomerular epithelial cell injury.Am J Physiol Renal Physiol. 2007 Jul;293(1):F148-56. doi: 10.1152/ajprenal.00294.2006. Epub 2007 Mar 20.
• [29] SPARC is expressed in renal interstitial fibrosis and in renal vascular injury.Kidney Int. 1996 Dec;50(6):1978-89. doi: 10.1038/ki.1996.520.
• [30] Effect of DP-1904, a thromboxane A2 synthase inhibitor, on passive Heymann nephritis in rats.Eur J Pharmacol. 1996 Nov 28;316(1):73-80. doi: 10.1016/s0014-2999(96)00662-0.
• [31] Fn14 in podocytes and proteinuric kidney disease.Biochim Biophys Acta. 2013 Dec;1832(12):2232-43. doi: 10.1016/j.bbadis.2013.08.010. Epub 2013 Aug 30.
• [32] Predicting risk of pulmonary infection in patients with primary membranous nephropathy on immunosuppressive therapy: The AIM-7C score.Nephrology (Carlton). 2019 Oct;24(10):1009-1016. doi: 10.1111/nep.13544. Epub 2019 Apr 29.
• [33] The putative role of MALDI-MSI in the study of Membranous Nephropathy.Biochim Biophys Acta Proteins Proteom. 2017 Jul;1865(7):865-874. doi: 10.1016/j.bbapap.2016.11.013. Epub 2016 Nov 24.
• [34] Chlormethine Hydrochloride is Not Inferior to Tacrolimus in Treating Steroid-Resistant Nephrotic Syndrome.Kidney Blood Press Res. 2018;43(1):68-79. doi: 10.1159/000486911. Epub 2018 Jan 24.
• [35] Involvement of the tubular ClC-type exchanger ClC-5 in glomeruli of human proteinuric nephropathies.PLoS One. 2012;7(9):e45605. doi: 10.1371/journal.pone.0045605. Epub 2012 Sep 24.
• [36] Biomarker prediction for membranous nephropathy prognosis by microarray analysis.Nephrology (Carlton). 2019 May;24(5):526-533. doi: 10.1111/nep.13446.
• [37] Overproduction of Mitochondrial Fission Proteins in Membranous Nephropathy in Children.Kidney Blood Press Res. 2018;43(6):1927-1934. doi: 10.1159/000496006. Epub 2018 Dec 14.
• [38] Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies.Nephrol Dial Transplant. 2017 Feb 1;32(2):325-332. doi: 10.1093/ndt/gfw001. Epub 2016 Feb 4.
• [39] HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-Related Membranous Nephropathy.J Am Soc Nephrol. 2017 May;28(5):1642-1650. doi: 10.1681/ASN.2016060644. Epub 2016 Dec 27.
• [40] Neurofilament heavy polypeptide protects against reduction in synaptopodin expression and prevents podocyte detachment.Sci Rep. 2018 Nov 21;8(1):17157. doi: 10.1038/s41598-018-35465-6.
• [41] Podocytes regulate the glomerular basement membrane protein nephronectin by means ofmiR-378a-3p in glomerular diseases.Kidney Int. 2017 Oct;92(4):836-849. doi: 10.1016/j.kint.2017.03.005. Epub 2017 May 3.
• [42] Identification and characterization of a new autoimmune protein in membranous nephropathy by immunoscreening of a renal cDNA library.PLoS One. 2012;7(11):e48845. doi: 10.1371/journal.pone.0048845. Epub 2012 Nov 8.
• [43] Pdlim2 is a novel actin-regulating protein of podocyte foot processes.Kidney Int. 2011 Nov;80(10):1045-54. doi: 10.1038/ki.2011.231. Epub 2011 Aug 3.
• [44] Phosphotriesterase-related protein sensed albuminuria and conferred renal tubular cell activation in membranous nephropathy.J Biomed Sci. 2014 Apr 22;21(1):32. doi: 10.1186/1423-0127-21-32.
• [45] Value of immunofluorescence-mediated detection of Ig, C1q, C3, and FRA for the identification and diagnosis of atypical membranous nephropathy.Eur Rev Med Pharmacol Sci. 2017 Dec;21(23):5415-5419. doi: 10.26355/eurrev_201712_13929.
• [46] Exostosin 1/Exostosin 2-Associated Membranous Nephropathy.J Am Soc Nephrol. 2019 Jun;30(6):1123-1136. doi: 10.1681/ASN.2018080852. Epub 2019 May 6.
• [47] Serum alpha 2-macroglobulin and alpha 1-inhibitor 3 concentrations are increased in hypoalbuminemia by post-transcriptional mechanisms.Kidney Int. 1998 Jan;53(1):67-75. doi: 10.1046/j.1523-1755.1998.00734.x.
• [48] Development of a novel cell-based assay to diagnose recurrent focal segmental glomerulosclerosis patients.Kidney Int. 2019 Mar;95(3):708-716. doi: 10.1016/j.kint.2018.10.030. Epub 2019 Jan 29.
• [49] Detection of terminal complement components in experimental immune glomerular injury.Kidney Int. 1984 Dec;26(6):830-7. doi: 10.1038/ki.1984.225.
• [50] Role of receptor-associated 39/45 kD protein in active Heymann nephritis.Kidney Int. 1995 Feb;47(2):432-41. doi: 10.1038/ki.1995.56.
• [51] Improvement of membranous nephropathy by inhibition of miR-193a to affect podocytosis via targeting WT1.J Cell Biochem. 2019 Mar;120(3):3438-3446. doi: 10.1002/jcb.27616. Epub 2018 Sep 22.
• [52] The transcriptional regulation of podocin (NPHS2) by Lmx1b and a promoter single nucleotide polymorphism.Cell Mol Biol Lett. 2009;14(4):679-91. doi: 10.2478/s11658-009-0026-0. Epub 2009 Jun 27.
• [53] Serum secretory phospholipase A2 group IB correlates with the severity of membranous nephropathy.Clin Chim Acta. 2018 Jul;482:178-184. doi: 10.1016/j.cca.2018.04.009. Epub 2018 Apr 9.
• [54] Early changes in gene expression that influence the course of primary glomerular disease.Kidney Int. 2007 Aug;72(3):337-47. doi: 10.1038/sj.ki.5002302. Epub 2007 Apr 25.
• [55] Alteration of histone H3K4 methylation in glomerular podocytes associated with proteinuria in patients with membranous nephropathy.BMC Nephrol. 2016 Nov 17;17(1):179. doi: 10.1186/s12882-016-0390-8.